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Abstract
Background: Epidermal growth factor receptor (EGFR) plays an essential role in normal development,
tumorigenesis and malignant biology of human cancers, and is known to undergo intracellular trafficking to
subcellular organelles. Although several studies have shown that EGFR translocates into the mitochondria in cancer
cells, it remains unclear whether mitochondrially localized EGFR has an impact on the cells and whether EGFRvIII, a
constitutively activated variant of EGFR, undergoes mitochondrial transport similar to EGFR.
Results: We report that both receptors translocate into the mitochondria of human glioblastoma and breast
cancer cells, following treatments with the apoptosis inducers, staurosporine and anisomycin, and with an EGFR
kinase inhibitor. Using mutant EGFR/EGFRvIII receptors engineered to undergo enriched intracellular trafficking into
the mitochondria, we showed that glioblastoma cells expressing the mitochondrially enriched EGFRvIII were more
resistant to staurosporine- and anisomycin-induced growth suppression and apoptosis and were highly resistant to
EGFR kinase inhibitor-mediated growth inhibition.
Conclusions: These findings indicate that apoptosis inducers and EGFR-targeted inhibitors enhance mitochondrial
translocalization of both EGFR and EGFRvIII and that mitochondrial accumulation of these receptors contributes to
tumor drug resistance. The findings also provide evidence for a potential link between the mitochondrial EGFR
pathway and apoptosis.
Background
EGFR is an important mediator of normal cell growth and
differentiation [1,2]. In cancer cells, EGFR is frequently
over-expressed and is associated with tumor proliferation,
progression and drug resistance [3-5]. EGFRvIII, a consti-
tutively activated EGFR variant, is a product of rearrange-
ment with an in-frame deletion of 801 bp of the coding
sequence of the EGFR extracellular domain that results in
a deletion of residues 6 through 273 and a glycine inser-
tion as residue 6 [6-9]. EGFR/EGFRvIII gene amplification
is frequent in glioblastoma multiforme (GBM), the most
common and deadliest brain cancer in adults [9,10].
Consequently, both EGFR and EGFRvIII are being tar-
geted for cancer therapy [3,11,12].
The anticancer efficacy of anti-EGFR small molecule
inhibitors and monoclonal antibodies has been evaluated
in clinical trials both as single agent and in combination
with other chemotherapeutic agents, but to date, have
shown only modest effects [13-18]. Much effort is thus
being directed at understanding the mechanisms that
underlie tumor resistance to anti-EGFR therapy. For
example, we have recently shown that nuclear EGFR inter-
acts with STAT3 and that the interaction contributes to
tumor resistance to the anti-EGFR agent, Iressa, in human
GBM [12] and breast cancer cells [19]. In addition, it has
been recently reported that EGFR and EGFRvIII interacts
with apoptotic protein PUMA and inhibits PUMA’s apop-
totic function [20]. PTEN loss has also been implicated in
resistance to EGFR inhibition, although, other studies did
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any medium, provided the original work is properly cited.not find such a linkage [17,18,21,22]. In lung cancer, gai-
n-of-function EGFR mutations have been shown to be
predictive of sensitivity to EGFR-targeted treatments, how-
ever, in other tumor types, these mutations are either
absent or are very rare. The biology underlying tumor
resistance to EGFR-targeted therapy is thus complex and
remains not well understood.
An area of EGFR-associated biology in human cancers
that is receiving increasing attention is the ability of
EGFR to escape lysosome-mediated degradation and
recycling to the plasma membranes and, subsequently, to
undergo intracellular trafficking to subcellular organelles,
such as, nuclei [4,19,23-25] and mitochondria [26,27].
Nuclear EGFR and mitochondrial EGFR are expressed as
the full-length proteins, in contrast to HER4/ErbB4
which enters nuclei and mitochondria as its C-terminal
fragment. While the cellular functions and role of nuclear
EGFR are becoming clearer, those of mitochondrial
EGFR are still largely unknown. Also unknown is
whether EGFRvIII undergoes mitochondrial translocali-
zation. Nevertheless, it has been shown that EGF stimula-
tion enhances EGFR mitochondrial localization in MDA-
MB-231 breast cancer cells [26] and that mitochondrial
EGFR interacts with cytochrome c oxidase subunit II
(CoxII) in an EGFR Y845-dependent manner [27]. EGFR
Y 8 4 5i sas p e c i f i cp h o s p h o r y l a t i o nr e s i d u et a r g e t e db y
c-Src and interestingly, c-Src appears to also undergo
mitochondrial import with kinetics similar to that of
EGFR [27]. In the mitochondria, both EGFR and c-Src
can phosphorylate Cox II, albeit the consequence of this
phosphorylation remains unclear [27].
Given the pivotal role that mitochondria plays in
intrinsic apoptosis, we investigated, in this study, the
effects of apoptosis-inducing agents on mitochondrial
translocalization of both EGFR and EGFRvIII. We also
conducted a series of experiments to address the impact
of the mitochondrial accumulation of EGFR and EGFR-
vIII on the apoptotic response of cancer cells treated
with apoptosis-inducing agents and an EGFR kinase
inhibitor, Iressa. Our findings demonstrate that both
EGFR and EGFRvIII undergo mitochondrial translocali-
zation when cancer cells encounter apoptotic stimuli.
Using cells that stably express EGFRvIII and mitochond-
rially enriched EGFRvIII mutant, we found that mito-
chondrial accumulation of EGFRvIII rendered the cells
highly resistant to apoptosis induced by these agents.
These results implicate mitochondrial EGFR/EGFRvIII
in the modulation of mitochondria-mediated apoptosis.
Results
EGFR mitochondrial translocalization is enhanced by
apoptotic inducers and an EGFR kinase inhibitor
The impact of apoptotic stimuli on EGFR mitochondrial
translocalization remains uninvestigated. Using human
GBM T98G cells that express high endogenous levels of
EGFR, we found that full-length EGFR undergoes
increased mitochondrial translocalization after treat-
ments with staurosporine (ST) and Iressa (I) for 15 min
(Figure 1A; left panel). Cell fractionation was effective as
indicated by the lack of the cytoplasmic marker, b-actin,
and the nuclear protein, lamin B, in the mitochondrial
extracts, as well as, by the absence of the mitochondrial
protein, Cox IV, in the non-mitochondrial extracts. As
shown by the right panel of Figure 1A, both treatments
have led to an increased level of total EGFR, suggesting
that they may regulate EGFR expression at the post-
translational level. The extent of EGFR mitochondrial
translocalization was subsequently computed and
expressed as an mtEGFR index. Notably, staurosporine
and Iressa increased the mtEGFR index by approxi-
mately 2.5- to 4-fold (Figure 1A). This was further con-
firmed using immunofluorescence staining and confocal
microscopy (Figure 1B), in which mitochondrial EGFR
was marked by the yellow fluorescence signals (arrows)
merged from the green fluorescence (EGFR) and red
fluorescence (mitochondria-specific dye, mitotracker).
The bottom panels of Figure 1B show high-resolution
images in which arrows point to mitochondrial EGFR
(yellow signals). The observations made in T98G cells
were similarly found in cells of the human breast cancer,
MDA-MB-468, that express endogenous EGFR (Figures
1C-1E), in which the two apoptosis-inducers, stauros-
porine and anisomycin, were used to stress the cells. As
shown by the right panel of Figure 1C, staurosporine
has modestly increased the level of total EGFR. Using
electron microscopy (Figure 1E), we observed that EGFR
was readily detected in the mitochondria of EGF-treated
tumor cells in which arrows mark gold particles that
label EGFR. As shown in Figure 1F, we further found
that staurosporine and Iressa induced EGFR mitochon-
drial transport in a time-dependent fashion peaking at 2
hrs after treatments. Notably, the majority of T98G cells
did not survive 24 hr staurosporine treatment as indi-
cated by the lack of b-actin and EGFR expression.
Noticeably, both the GBM and breast cancer cell lines
we analyzed contained a basal level of mitochondrial
EGFR without stimulation. This may be due to an auto-
crine effect given the ability of EGF to induce EGFR
mitochondrial translocalization [26]. Together, these
results indicate that apoptotic stimuli enhance EGFR
mitochondrial translocalization in human cancer cells.
EGFRvIII undergoes mitochondrial translocalization and
the degree of transport is enhanced by apoptosis
inducers and Iressa
It remains uninvestigated whether EGFRvIII translocates
into the mitochondria. Using cell fractionation and wes-
tern blotting, we show that EGFRvIII is present in the
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Page 2 of 13mitochondria even under unstressed condition but that
the level is enhanced by apoptotic stress (Figure 2A).
The molecular weight of the mitochondrially seque-
strated EGFRvIII is approximately 145 kD, similar to the
full-length EGFRvIII. In these studies, we used U87MG-
EGFRvIII cells that we previously established to express
stably transfected EGFRvIII [12] because endogenous
EGFRvIII expression is not maintained in vitro [28]. As
indicated by the mtEGFRvIII indices, staurosporine (ST)
and anisomycin (AN) increased the levels of mitochon-
drial EGFRvIII by approximately 3-4 fold, while Iressa
resulted in a 7.5-fold increase in EGFRvIII mitochon-
drial transport (Figure 2B). These observations were
confirmed by immunofluorescence staining and confocal
microscopy (Figure 2C). In the immunofluorescence
staining experiments, we used an EGFR antibody that
Figure 1 EGFR undergoes enhanced mitochondrial translocalization after exposures to apoptosis inducers and the EGFR kinase
inhibitor, Iressa. A, An apoptotic inducer and an EGFR kinase inhibitor enhance EGFR mitochondrial transport. Human T98G GBM cells with
high endogenous levels of EGFR were treated with and without 1 uM staurosporine (ST) and 12.5 uM Iressa (I) for 15 min, fractionated into
mitochondrial and non-mitochondrial fractions, and analyzed by western blotting. The extent of EGFR mitochondrial translocalization was
indicated by mtEGFR index. Right panel: western blots with whole cell lysates. B, Immunofluorescence staining/confocal microscopy showing
staurosporine- and Iressa-induced EGFR mitochondrial translocalization. T98G cells were similarly treated as in Panel A, fixed and subjected to
immunofluorescence staining/confocal microscopy to mark mitochondrial EGFR. Mitochondrial EGFR (arrows) is shown as the yellow signals
merged from the green fluorescence (EGFR) and the red fluorescence (mitotracker, a mitochondria-specific dye). Bottom panels: high-resolution
images. C, Endogenous EGFR in breast cancer MDA-MB-468 cells undergoes staurosporine-induced mitochondrial transport. The cells were
treated with and without staurosporine (ST) for 15 min, fractionated and subjected to western blotting. Right panel shows western blots with
whole cell lysates. D, Anisomycin stimulates EGFR mitochondrial translocalization in MDA-MB-468 cells. The cells were treated with and without
100 ng/ml anisomycin for 15 min and subjected to immunofluorescence staining/confocal microscopy, as described earlier in Panel B. Arrows:
representative EGFR signals in the mitochondria. E, EM shows mitochondrial presence of EGFR in EGF-treated tumor cells. Arrows point to EGFR
signals in the mitochondria. Right panels show high-resolution images. Mitochondrion is labeled as M. Nucleus is labeled as Nu. F, Staurosporine
and Iressa induced EGFR mitochondrial transport in a time-dependent fashion peaking at 2 hrs after treatments. The majority of T98G cells did
not survive 24 hr staurosporine treatment as indicated by the lack of b-actin and EGFR expression.
Cao et al. Molecular Cancer 2011, 10:26
http://www.molecular-cancer.com/content/10/1/26
Page 3 of 13recognized the N-terminal epitope present in both
EGFR and EGFRvIII (Figure 2C) and a Myc-tag antibody
that bound to the C-terminal Myc-tag of the EGFR/
EGFRvIII fusion proteins (data not shown). The results
showed that both antibodies labeled mitochondrial
EGFRvIII. This observation combined with that of the
western blotting (Figure 2A)s t r o n g l yi n d i c a t et h a tt h e
mitochondrially localized EGFRvIII is likely to be the
full-length EGFRvIII.
Amino acid substitutions of N-terminal conserved motifs
increase mitochondrial import of both EGFR and EGFRvIII
In this study, we targeted two N-terminal regions of
EGFR and EGFRvIII that are homologous to L/I/V/F/M-
rich sequences that have been shown to be involved in
protein intracellular trafficking [29-31]. As shown in
Figures 3A and 3B, the two N-terminal motifs are pre-
sent in the extracellular region of EGFR, EGFRvIII and
HER2 while the second motif is found in all members of
Figure 2 EGFRvIII translocates into mitochondria even under unstressed condition but the transport is enhanced by apoptosis
inducers and EGFR inhibition. Since endogenous EGFRvIII expression is not maintained in vitro [28], we used U87MG-EGFRvIII stable
transfectant cells expressing EGFRvIII [12] in these studies. A, Full-length EGFRvIII is present in the mitochondria under unstressed condition and
the level is enhanced by apoptotic stress and Iressa. Cancer cells treated with and without 1 uM staurosporine (ST) and 100 ng/ml anisomycin
(AN) for 15 min were fractionated into mitochondrial and non-mitochondrial fractions followed by western blotting. Full-length EGFRvIII was
detected in both extracts. The mtEGFRvIII indices indicate that staurosporine and anisomycin increased the levels of mitochondrial EGFRvIII by
approximately 3-4 folds. B, Iressa induces significant mitochondrial transport of EGFRvIII. Cancer cells were treated with and without 12.5 uM
Iressa, an EGFR kinase inhibitor, for 15 min and subjected to cell fractionation and western blotting. Effectiveness of cell fractionation was
indicated by the lack of the cytoplasmic marker b-actin and a nuclear protein lamin B in the mitochondrial extracts, as well as, by the absence of
the mitochondrial protein Cox IV in the non-mitochondrial extracts. The mtEGFRvIII indices indicate that Iressa resulted in a marked increase (7.5-
fold) of mitochondrial EGFRvIII. C, Immunofluorescence staining and confocal microscopy confirmed staurosporine-, anisomycin and Iressa-
induced EGFRvIII mitochondrial import. In these studies, we used an EGFR antibody that recognized the N-terminal epitope in EGFRvIII and the
Myc antibody that bound to the C-terminal Myc-tag of the EGFRvIII fusion protein (data not shown) and found both antibodies to detect
mitochondrial EGFRvIII. This observation and the molecular weight shown in western blotting suggest that the mitochondrially localized EGFRvIII
is highly likely to be the full-length protein.
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among EGFR proteins in different mammalian species
(Figure 3C). To determine the role of these motifs in
modulating EGFR/EGFRvIII intracellular trafficking, we
performed site-directed mutagenesis to substitute leu-
cine/isoleucine residues with alanines and thereby,
altered the L/I-rich property of the motifs. Conse-
quently, we generated two EGFR mutants, EGFR-MTS1
(L399A/I402A) and EGFR-MTS2 (L429A/I432A) and
two EGFRvIII mutants (Figure 3D), EGFRvIII-MTS1
(L132A/I35A) and EGFRvIII-MTS2 (L162A/I165A). The
subcellular location of these EGFR/EGFRvIII mutants
was then examined via immunofluorescence staining/
confocal microscopy following transfecting the mutant
constructs into EGFR/EGFRvIII-null Chinese hamster
ovary (CHO) cells. The results (Figure 3E) showed that
all four mutant receptors were significantly localized in
the mitochondria, as indicated by the yellow signals
Figure 3 Amino acid substitutions of the N-terminal conserved motifs enhance mitochondrial targeting of both EGFR and EGFRvIII. A,
Structures of the two N-terminal conserved motifs within EGFR and EGFRvIII. The two motifs are homologous to the L/I/V/F/M-rich sequence
that has been shown to involve in protein intracellular trafficking [29-31]. Notably, the first motif is present in EGFR, EGFRvIII and HER2 while the
second motif is found in all members of the EGFR family of receptors. B, Simplified structures of EGFR/EGFRvIII show that both sequences are
present in the extracellular region of both receptors. TM, transmembrane domain. N, nuclear-localization signal. I, internalization domain. C, Both
motifs are conserved among EGFR proteins in different mammalian species. D, EGFRvIII mutants with amino acid substitutions within the
conserved motifs. To determine the role of the motifs in modulating EGFR/EGFRvIII intracellular trafficking, we performed site-directed
mutagenesis to substitute leucine/isoleucine residues to alanines, thereby altering the L/I-rich property of the motifs. E, EGFR-MTS and EGFRvIII-
MTS mutants demonstrate enhanced degrees of mitochondrial localization. Using immunofluorescence staining/confocal microscopy, we
examined subcellular location of EGFR/EGFRvIII and all four mutants in EGFR/EGFRvIII-null CHO cells. The yellow signals indicate mitochondrially
localized receptors, merged products of the green fluorescence (receptors) and red fluorescence (mitochondrion labeled by mitotracker). F,G,
The EGFR-MTS1 mutant did not display enhanced nuclear accumulation as shown by immunofluorescence staining and confocal microscopy
(Panel F) and nuclear fractionation followed by western blotting (Panel G). Transfected CHO cells were serum-starved and treated with and
without EGF (100 ng/ml) for 10 min to induce EGFR nuclear import. The results showed that the EGFR MTS mutants did not have enhanced
nuclear accumulation, in contrast to their ability to richly localize in the mitochondria (EGFR-MTS2 data not shown).
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and their mutants) with the red fluorescence (mitochon-
drion). EGFR and EGFRvIII MTS mutant proteins were
also present in the cytoplasm. Interestingly, the MTS
mutants were rarely found on the plasma membranes.
Given the similarity of the two N-terminal motifs to the
reported nuclear-export signals [30], we determined
whether the mutations within the motifs block EGFR
nuclear export and consequently, facilitate EGFR
nuclear accumulation. The results of immunofluores-
cence staining and confocal microscopy (Figure 3F)
showed no increased accumulation of EGFR-MTS1 or
EGFR-MTS2 (not shown) in the nucleus, despite their
ability to undergo significant mitochondrial import.
This was confirmed using nuclear fractionation followed
by western blotting (Figure 3G), in which the effective-
ness of nuclear fractionation was indicated by the
absence of the cytoplasmic protein b-actin in the
nucleus and the lack of the nuclear protein histone H3
in the non-nuclear extracts. Collectively, these results
indicate that the EGFR/EGFRvIII MTS mutants undergo
enhanced mitochondrial translocalization. These data
also suggest that these mutants can be used as valuable
tools for studies aiming to elucidate the actions of mito-
chondrial EGFR/EGFRvIII that are largely unknown at
the present time.
Tumor cells expressing the mitochondrially enriched
EGFRvIII are more resistant to mitochondria-mediated
apoptosis
In light of our observations that apoptotic stimuli
induced EGFR/EGFRvIII translocation into the mito-
chondria, a focal point of intrinsic apoptosis initiation,
we speculated that mitochondrial EGFR/EGFRvIII may
be involved in mediating mitochondria-mediated apop-
tosis. Consequently, we created two U87MG stable
transfectant cell lines, U87MG-EGFRvIII-MTS1 and
U87MG-EGFRvIII-MTS2, to respectively express EGFR-
vIII-MTS1 and EGFRvIII-MTS2 mutants. As shown in
Figure 4A, the expression levels of the transgenes in
U87MG-EGFRvIII-MTS1 and U87MG-EGFRvIII-MTS2
stable transfectant cells were similar to that of U87MG-
EGFRvIII cells. The two MTS mutants are expressed at
high levels in the mitochondria as shown by the results
of immunofluorescence staining/confocal microscopy
(Figure 4B) and cell fractionation/western blotting
(Figure 4C; only EGFR-MTS1 data are shown; ME,
mitochondrial extracts; NME, non-mitochondrial
extracts). Stability of EGFRvIII, EGFRvIII-MTS1 and
EGFRvIII-MTS2 proteins was similar, as indicated by
the protein degradation study using the transcription
inhibitor, cycloheximide (Figure 4D; data for EGFRvIII-
MTS2 are not shown). Given the observation that
EGFRvIII-MTS1 and EGFRvIII-MTS2 behave similarly,
we focused on EGFRvIII-MTS1 for determining the
effects of EGFRvIII mitochondrial accumulation on the
response of cancer cells to apoptosis-inducing agents.
We observed that U87MG-EGFRvIII-MTS1 cells were
more resistant to 48 hr treatments of staurosporine (Fig-
ure 5A) and anisomycin (Figure 5B) than U87MG-
EGFRvIII cells. Consistent witht h e s eo b s e r v a t i o n s ,a n i -
somycin induced a significantly lower level of apoptosis
in U87MG-EGFRvIII-MTS1 cells than in U87MG-
EGFRvIII cells (Figure 5C). In the TUNEL assay, the
extent of apoptosis was indicated by the yellow fluores-
cence signals, merged products of the red fluorescence
(nuclei) and the green (fluorescence fragmented DNA).
Together, these results suggest that EGFRvIII mitochon-
drial accumulation protects cancer cells from under-
going mitochondria-mediated apoptotic death.
Translocation of EGFRvIII to mitochondria renders tumor
cells resistant to EGFR inhibition
The results summarized in Figure 2 indicate that the
EGFR inhibitor, Iressa, enhances EGFRvIII mitochon-
drial translocalization in tumor cells. We, therefore,
examined whether the mitochondrial accumulation of
EGFRvIII impacts cancer cell sensitivity to Iressa. The
results of these studies, summarized in Figure 6A, show
that U87MG-EGFRvIII-MTS1 cells with increased mito-
chondrial EGFRvIII are significantly more resistant to a
48-hr Iressa treatment than control U87MG-EGFRvIII
cells. This is further confirmed by the results of the clo-
nogenic cell assay (Figures. 6B and 6C), showing that
control U87MG-EGFRvIII-MTS1 cells had a reduced
ability to form colonies compared to untreated U87MG-
EGFRvIII cells. This interesting observation may be due
to the likelihood that EGFRvIII-MTS1 is mitochondrially
enriched for the purpose of enhancing survival and that
it is rarely localized on the cell-surface where the mito-
genic proliferative signal is transmitted. These results
combined with those in Figure 2 indicate that Iressa
induces EGFRvIII mitochondrial translocalization and
that the mitochondrial accumulation of EGFRvIII contri-
butes to the resistance of GBM cells to EGFR inhibition.
Discussion
We report in this study that both EGFR and EGFRvIII
translocate into mitochondria upon exposure of GBM
and breast cancer cells to apoptosis inducers and EGFR
inhibitors and that accumulation of EGFRvIII in mito-
chondria renders GBM cells more resistant to the EGFR
inhibitor, Iressa, and other apoptosis inducers. Two
modes of EGFR signaling, cell-surface and nuclear, have
been well characterized to play important roles in
human cancers [3-5]. The cell-surface EGFR signaling
pathway occurs through transduction of mitogenic
signals from the cell-surface to PLC-g-CaMK/PKC,
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downstream to targets in the cytoplasm and the cell
nucleus. The nuclear EGFR pathway involves EGFR
nuclear transport and can be activated by ligand bind-
ing, radiation, cisplatin, heat- and oxidative-stress, and
inhibited by exposure to vitamin D [4,32,33]. Nuclear
EGFR functions as a transcription factor and tyrosine
kinase, leading to increased proliferation and poor clini-
cal outcomes in cancer [4,19,25,33-36]. Our findings in
this study provide for and extend the previously
described mitochondrial EGFR signaling by demonstrat-
ing the functional consequences of mitochondrial EGFR
translocalization, specifically, its impact on apoptosis
and drug resistance.
Our findings confirm those in previous reports
[26,27,37] indicating that the full-length EGFR translo-
cates into the mitochondria. We also demonstrate, for
the first time, that EGFRvIII also translocates to
mitochondria as a full-length protein. This contrasts
with HER2, which has been shown to exist as both full-
length (185 kD) and truncated (155 kD) proteins in the
mitochondria of normal kidney and breast cells, and in
SK-BR-3 breast cancer cells [38]. In contrast to EGFR
and HER2, HER4 undergoes g-secretase processing [39]
and the resulting intracellular domain translocates into
the mitochondria [40]. In the case of EGFR, the full-
length receptor has been shown to exist in the cyto-
plasm as free non-membrane-bound form [41] and this
is the consequence of Sec61b translocon-mediated
retro-translocation that extract membrane-bound EGFR
from the ER to the cytoplasm as a non-membrane-
bound receptor [41]. In this form, EGFR interacts with
importin b1, a nuclear import protein, crosses through
nuclear pore complex into the nucleus, where it func-
tions as a transcription factor and tyrosine kinase
[35,42]. We recently showed that the non-membrane-
Figure 4 Cancer cells expressing the mitochondrially enriched EGFRvIII mutant are more resistant to apoptosis. A, Generation of U87MG
stable transfectant cell lines that express EGFRvIII-MTS1 and EGFRvIII-MTS2. Western blotting shows that the three isogenic cell lines express
equivalent levels of the transgenes. B,C, The EGFRvIII-MTS1 mutant is enriched in the mitochondria as shown by immunofluorescence staining
and confocal microscopy (B) and cell fractionation/western blotting (C). D, Stability of EGFRvIII and EGFRvIII-MTS1 proteins is similar. Protein half-
life study using transcription inhibitor cycloheximide determined the two proteins to have similar degradation rates.
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pro-apoptotic protein PUMA and traps PUMA in the
cytoplasm [20]. These observations are in line with the
notion that full-length EGFR translocates into the mito-
chondria, as shown in this study and in previous other
reports [26,27,37].
It remains unknown how EGFR or EGFRvIII translo-
cate into mitochondria, particularly, since both receptors
lack any of the known mitochondrial targeting signal
(MTS). Interestingly, a number of cytoplasmic and
nuclear proteins have been shown to undergo mitochon-
drial translocalization including, HER2 that lacks MTS.
Similarly, p53 does not contain a MTS but translocates
i n t ot h em i t o c h o n d r i ai nr e s p o n s et oD N Ad a m a g e ,
leading to apoptosis [43-45]. The transmembrane glyco-
protein, MUC1, also lacks a MTS but undergoes
proteolytic cleavage in ER, retro-translocated into cyto-
plasm and subsequently, its C-terminal peptide, MUC1-
C localizes to the mitochondria [46]. It has been shown
that MUC1-C forms intracellular complexes with cha-
perone HSP70/HSP90 complex [47] which enables its
mitochondrial trafficking. In light of these observations,
future investigations are warranted to explore whether
EGFR/EGFRvIII utilizes a similar chaperone mechanism
to gain entry into mitochondria.
Emerging evidence indicates that cell-surface and
nuclear proteins translocate into mitochondria and that
while in the mitochondria, elicit biological effects that
are uniquely distinct from their cell-surface and nuclear
functions. For example, cell-surface receptors (EGFR,
EGFRvIII and HER2), cytoplasmic proteins (c-Src, intra-
cellular domains of HER4 and MUC-1) and nuclear
Figure 5 U87MG-EGFRvIII-MTS1 cells were more resistant to apoptosis inducers than U87MG-EGFRvIII cells. A,B, U87MG-EGFRvIII-MTS1
cells survived better than U87MG-EGFRvIII cells after treatments of apoptosis inducers. The cells were exposed to staurosporine (0-2 uM; Panel A)
and anisomycin (0-200 ng/ml; Panel B) for 24 and 48 hrs and the survival rates determined using the Celltiter Blue Cell Survival Assay (Promega).
C, U87MG-EGFRvIII-MTS1 cells are more resistant to anisomycin-induced apoptosis than U87MG-EGFRvIII cells. The extent of apoptosis was
determined via the TUNEL assay, in which fragmented DNA is indicated by the yellow fluorescence signals, merged products of the red
fluorescence (nuclei) and the green fluorescence (fragmented DNA).
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some of them have been shown to elicit unique func-
tions [26,27,37,38,43-48]. We show in this study that
mitochondrial transport of EGFR and EGFRvIII can be
induced by apoptosis-inducing agents and EGFR inhibi-
tors and that tumor cells with accumulated mitochon-
drial EGFRvIII are resistant to apoptosis induced by
these agents. It has been previously shown that EGF sti-
mulates EGFR mitochondrial import leading to mito-
chondrial interaction of EGFR with Cox II; the cellular
consequence of the interaction, however, remains
unclear [26,27]. The role of HER2 in the mitochondria
is unknown. C-terminal region of HER4 binds to and
antagonizes anti-apoptotic protein Bcl-2 and thereby
promotes apoptosis of breast cancer cells [40]. Mito-
chondrial MUC1 has been shown to prevent cisplatin-
induced apoptosis [46]. Mitochondrial p53 binds to
anti-apoptotic protein Bcl-xL and induces apoptosis
[43-45]. It is worth noting that a recent study by Yue
et al [37] showed that EGFR mitochondrial translocation
can be increased by the mTOR inhibitor, rapamycin,
and decreased by the topoisomerase inhibitor, etoposide,
and by 3’-methyladenine, an inhibitor of autophagy. The
reported link between autophagy and mitochondrial
EGFR is particularly interesting and is in line with our
observation that apoptotic stress induces EGFR mito-
chondrial transport. Together, the results of Yue et al
[37] and the current study implicate mitochondrial
EGFR in apoptosis and autophagy of therapy-challenged
tumor cells. These findings also call for additional
efforts to elucidate the exact actions of mitochondrially
l o c a l i z e dE G F Ra n dE G F R v I I Ia n dt h e i ri m p a c to n
tumor response to anti-cancer drugs that often induce
apoptosis and/or autophagy.
Figure 6 Expression of the mitochondrially enriched EGFRvIII renders GBM cells more resistant to the EGFR inhibitor, Iressa. A, U87MG-
EGFRvIII-MTS1 cells are significantly more resistant to a 48-hr Iressa treatment (0-100 uM) than U87MG-EGFRvIII cells. Survival rates were
determined by the Celltiter Blue Cell Survival Assay. B,C, Clonogenic growth assay confirmed the results of Panel A. The assay was performed in
6-well cell culture plates as previously described [19]. Seeded cells were treated with 1% DMSO or 12.5 μM Iressa in 1% DMSO for 24 hrs
followed by medium replacement with fresh drug-free growth medium and culturing for 10-14 days. Colonies were stained with crystal violet
blue solution for 1 hr, washed with water, dried and counted. Triplicate wells were used for each treatment and three independent experiments
were performed to derive means and standard deviations. Student t-test was performed to compute p-values. Notably, U87MG-EGFRvIII-MTS1
cells are significantly more resistant to Iressa-mediated cell kill than U87MG-EGFRvIII cells. It is also noticeable that under the unstressed
condition, U87MG-EGFRvIII-MTS1 cells had a reduced ability to form colonies compared to U87MG-EGFRvIII cells.
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Our findings in this study indicate that apoptosis indu-
cers and EGFR-targeted inhibitors enhance mitochon-
drial translocalization of both EGFR and EGFRvIII and
that mitochondrial accumulation of these receptors con-
tributes to tumor drug resistance. The findings also pro-
vide evidence for a potential link between the
mitochondrial EGFR pathway and apoptosis. These
results also suggest that tumor cells may re-program
their intracellular trafficking of EGFR by increasing its
mitochondrial accumulation, as a mechanism for escape
from therapy- and stress-induced apoptosis and growth
suppression. The exact mechanisms by which mitochon-
drial EGFR modulates apoptotic response are currently
being investigated in our laboratory.
Methods
Cell lines and cell culture
Human GBM T98G and U87MG cells, human breast
carcinoma MDA-MB-468 cells and Chinese hamster
ovary (CHO) cells were obtained from American Type
Culture Collection (Manassas, VA). U87MG-EGFRvIII
stable transfectant cells were established from the paren-
tal U87MG cells that expressed a very low level of wild-
type EGFR as previously described [19]. All cell lines
were cultured in DMEM with 10% fetal calf serum while
the U87MG stable transfectant cell lines were addition-
ally supplemented with 0.7 mg/ml G418.
Reagents and chemicals
All chemicals were purchased from Sigma (St. Louis,
MO) unless otherwise stated. Rabbit polyclonal antibody
against EGFR (sc-05) used in western blotting was pur-
chased from Santa Cruz Biotech. (Santa Cruz, CA).
Monoclonal mouse EGFR antibody used in immuno-
fluorescence staining was obtained from Zymed. Mouse
monoclonal Myc-tag antibody was from Roche (Indiana-
polis, IN). Lamin B mouse monoclonal antibody was
from Calbiochem (San Diego, CA). Mouse monoclonal
b-actin and a-tubulin antibodies were obtained from
Sigma. Rabbit polyclonal Cox IV antibody was from
Abcam (Cambridge, MA). Mouse monoclonal anti-
EGFR antibody used in immunofluorescence staining
was from Zymed/Invitrogen (Carlsbad, CA). Mitotracker
was purchased from Invitrogen/Molecular Probes. All
transfections were performed with cells in exponential
growth using lipofectamine 2000 (Invitrogen) and
FuGENE HD (Roche). Iressa was purchased from LC
Laboratories (Woburn, MA). CellTiter Blue Cell Viabi-
lity Assay was obtained from Promega (Madison, WI).
Mitochondrial isolation kit was from Pierce (Rockford,
IL). QuikChange Mutagenesis Kit was from Stratagene
(Madison, WI).
Determination of EGFR/EGFRvIII mitochondrial
translocalization
For this, mitochondria were isolated from tumor cells
using a commercial kit (Pierce), according to the manu-
facturer’s instructions. Both mitochondrial and non-
mitochondrial fractions were subjected to protein
extraction using 1% SDS and 0.1% NP-40 and sonication
followed by centrifugation at 15,000 × g and 4°C for
20 min. In these studies, we subjected 25% of the mito-
chondrial proteins and 2.5% of the non-mitochondrial
proteins to western blotting. Band signals from mito-
chondrial EGFR/EGFRvIII and non-mitochondrial
EGFR/EGFRvIII were determined densitometrically
using the NIH ImageJ software, as we previously
described [49], and normalized against loading controls,
Cox IV and b-actin/a-tubulin. The extent of EGFR/
EGFRvIII mitochondrial translocalization, designated as
mtEGFR/EGFRvIII Index, was computed using the equa-
tion: (mitochondrial EGFR/EGFRvIII ÷ 25%)/(mitochon-
drial EGFR/EGFRvIII ÷ 25%) + (non-mitochondrial
EGFR/EGFRvIII ÷ 2.5%).
Detection of mitochondrial EGFR/EGFRvIII via
immunofluorescence staining and confocal microscopy
Tumor cells seeded in 8-well Lab-Tek chamber slides
(Nunc Inc., Rochester, NY) for 24 hrs were washed with
ice-cold PBS, fixed in 4% paraformaldehyde for 15 min
and permeablized with 0.2% Triton-X100 for 5 min. Fol-
lowing treatment with 10% normal goat serum/1% BSA
for 60 min, the cells were incubated with polyclonal rab-
bit Myc or monoclonal mouse EGFR antibody overnight
at 4°C. After three washes with PBS, the cells were incu-
bated with goat anti-rabbit secondary or donkey anti-
mouse antibodies (1:200, Vector Lab) tagged with Texas
Red or fluorescein, respectively. To label the mitochon-
dria, the cells were additionally exposed to DMEM con-
taining 200 nM mitotracker for 30 min prior to fixation
in 4% paraformaldehyde. They were then mounted with
VECTASHIELD Mounting Medium with and without
propidium iodide (for nuclei detection) and examined
under a Zeiss LSM 510 confocal microscope.
Detection of mitochondrial EGFR by transmission electron
microscopy (EM)
MDA-MB-468 breast cancer cells were subjected to EM
analysis. Briefly, following incubation with mouse IgG,
cell sections were treated with mouse monoclonal EGFR
antibody. The cells were then incubated with gold parti-
cle (15 nm) labeled goat anti-mouse secondary antibody
(Amersham Biosciences, USA) for 45 min. Sections were
washed, stained with uranyl acetate for 2 min and Rey-
nolds’s lead citrate for 1 min and examined in a Jeol
1200EX microscope.
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mitochondrial presence using site-directed mutagenesis
This was performed using QuikChange Mutagenesis Kit
(Stratagene) and PCR, according to the manufacturer’s
instructions [24]. The plasmids carrying EGFR and
EGFRvIII cDNAs, namely, pCMV-Tag5A-EGFR and
pCMV-Tag5A-EGFRvIII [12], were used as templates in
the PCR-mutagenesis reactions. Primers used to gener-
ate EGFR-MTS1 and EGFRvIII-MTS1 mutants are
5’-ATGCCTTTGAGAACGCAGAAATCGCACGCGGCA
GGA-3’ (forward) and 5’-TCCTGCCGCGTGCG AT
TTCTGCGTTCTCAAAGGCAT-3’ (reverse). To produce
EGFR-MTS2 and EGFRvIII-MTS2, primers with the
sequences of 5’-GATTACGCTCCGCAAGGAGGCAAG
TGATGGAGATG-3’ (forward) and 5’-CATCTCCATC
ACTTGCCTCCTTGGCGGAGCGTAATC-3’ (reverse)
were used. Subsequently, the EGFRvIII-MTS1 and EGFR-
vIII-MTS2 constructs were transfected into U87MG GBM
cells to establish U87MG-EGFRvIII-MTS1 and U87MG-
EGFRvIII-MTS2 stable transfectant cell lines.
Nuclear fractionation and western blotting
This was performed as previously described [24,50].
Briefly, serum-starved cells treated with EGF (100 ng/
ml) for 0 and 10 mins were collected, washed with PBS,
and swelled in hypotonic buffer (25 mM Tris-HCl, pH
7.5, 5 mM KCl, 0.5 mM dithiothreitol, 1 mM PMSF and
0.15 m/ml aprotinin) for 20 min on ice. Following
homogenization using a Dounce homogenizer, nuclei
were pelleted and washed. Ultrasonic disruption was
used to extract nuclear proteins from the isolated nuclei.
To isolate non-nuclear extracts, the supernatant was
exposed to 1% SDS and 0.1% NP-40, centrifuged at
15,000 g to remove cell debris and the resulting super-
natant collected. Western blotting was conducted. His-
tone H3 serves a nuclear marker.
Determination of half-life of EGFRvIII and its MTS mutants
Tumor cells exposed to 10 ug/ml cycloheximide for 0,
30, 60, 120 and 180 min were harvested, total proteins
extracted and subjected to western blotting. A Myc-
tagged mouse monoclonal antibody (Roche) was used to
detect Myc-tagged EGFRvIII and EGFRvIII-MTS fusion
proteins. Membranes were also blotted with an anti-a-
tubulin antibody (Sigma).
TUNEL assay for apoptosis
This was performed using a TUNEL assay kit (Invitro-
gen), according to the manufacturer’s instructions [20].
Briefly, the cells were fixed in 70% ethanol, washed and
incubated with the labeling solution containing 5-bro-
modeoxyuridine 5’-triphosphate and deoxynucleotidyl
terminal transferase for 1 hr at 37°C. The DNA incorpo-
rated bromodeoxyuridine was detected by Alexa Fluor
®
488 dye-labeled anti-BrdU antibody at room tempera-
ture for 30 min. The cells were then counterstained
with propidium iodide and observed under a Zeiss LSM
510 confocal microscope. Yellow signals indicate nuclear
fragmented DNA, the merged products of fragmented
DNA (green fluorescence) and nuclei (red fluorescence).
A total of 250-300 cells were examined in each experi-
ment and three independent experiments were con-
ducted to derive means and standard deviations. Extent
of apoptosis was subsequently computed using the equa-
tion, (# of nuclei with fragmented DNA)/(# of total
nuclei).
Cell survival and clonogenic growth assays
Tumor cells in exponential growth were seeded in
96-well culture plates and treated with vehicle control
(1% DMSO) and various agents. After 48 hrs, the cells
were subjected to cell survival analyses using the CellTi-
ter Blue Cell Viability Assay (Promega). Briefly, 25 μlo f
the CellTiter Blue reagent was added to each well con-
taining 100 ul media, incubated for 4 hrs at 37°C, and
then the absorbance measured at 560 nm/590 nm using
a plate reader (Synergy-HT, BIO-TEK, Winooski, VT).
Clonogenic growth assay was performed in 6-well cell
culture plates with 1,000 cells seeded per well as pre-
viously described [19]. Seeded cells were treated with
1% DMSO or 12.5 μM Iressa in 1% DMSO for 24 hrs,
medium removed and replaced with fresh drug-free
growth medium for 10-14 days. Colonies were stained
with crystal violet blue solution (Sigma) for 1 hr, washed
with water, dried and counted. Triplicate wells were
used for each treatment and three independent experi-
ments were performed to derive means and standard
deviations.
Statistical analysis
Student t-test was performed using STATISTICA (Stat-
Soft Inc., Tulsa, OK) and Microsoft Excel.
Acknowledgements
This work was supported by NIH grant 5K01-CA118423, DoD grant
W81XWH-07-1-0390, Pediatric Brain Tumor Foundation and Beez Foundation
(to HWL).
Author details
1Division of Surgical Sciences, Department of Surgery, Duke University
School of Medicine, 433A MSRB I, 103 Research Drive, Durham, NC 27710,
USA.
2Duke Comprehensive Cancer Center, Durham, NC 27710, USA.
3Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC
27710, USA.
4Department of Pharmacology, Box 7365, University of North
Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
Authors’ contributions
XC carried out mitochondrial and nuclear fractionations, western blotting
studies and determination of protein half-life and participated in the cancer
cell culture. HZ performed mutagenesis and generation of stable
transfectant cells, and carried out the immunofluorescence staining and
Cao et al. Molecular Cancer 2011, 10:26
http://www.molecular-cancer.com/content/10/1/26
Page 11 of 13confocal microscopy and cell survival assays. FAO helped to revise the
manuscript. HWL conceived of the study, designed and coordinated the
project and wrote the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 September 2010 Accepted: 9 March 2011
Published: 9 March 2011
References
1. Cohen S, Fava RA, Sawyer ST: Purification and characterization of
epidermal growth factor receptor/protein kinase from normal mouse
liver. Proc Natl Acad Sci USA 1982, 79:6237-6241.
2. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological
effects in vitro of monoclonal antibodies to human epidermal growth
factor receptors. Mol Biol Med 1983, 1:511-529.
3. Lo HW: EGFR-targeted therapy in malignant glioma: novel aspects and
mechanisms of drug resistance. Curr Mol Pharmacol 2010, 3:37-52.
4. Lo HW: Nuclear mode of the EGFR signaling network: biology,
prognostic value, and therapeutic implications. Discov Med 2010,
10:44-51.
5. Lo HW, Hung MC: Nuclear EGFR signalling network in cancers: linking
EGFR pathway to cell cycle progression, nitric oxide pathway and
patient survival. Br J Cancer 2006, 94:184-188.
6. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M: A deletion mutation within
the ligand binding domain is responsible for activation of epidermal
growth factor receptor gene in human brain tumors. Jpn J Cancer Res
1990, 81:773-779.
7. Ekstrand AJ, Sugawa N, James CD, Collins VP: Amplified and rearranged
epidermal growth factor receptor genes in human glioblastomas reveal
deletions of sequences encoding portions of the N- and/or C-terminal
tails. Proc Natl Acad Sci USA 1992, 89:4309-4313.
8. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS,
Vogelstein B: Structural alterations of the epidermal growth factor
receptor gene in human gliomas. Proc Natl Acad Sci USA 1992,
89:2965-2969.
9. Sugawa N, Ekstrand AJ, James CD, Collins VP: Identical splicing of
aberrant epidermal growth factor receptor transcripts from amplified
rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990,
87:8602-8606.
10. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B:
Increased expression of the epidermal growth factor receptor gene in
malignant gliomas is invariably associated with gene amplification. Proc
Natl Acad Sci USA 1987, 84:6899-6903.
11. Lo HW, Hsu SC, Hung MC: EGFR signaling pathway in breast cancers:
from traditional signal transduction to direct nuclear translocalization.
Breast Cancer Research and Treatment 2006, 95:211-218.
12. Lo HW, Cao X, Zhu H, Ali-Osman F: Constitutively activated STAT3
frequently coexpresses with epidermal growth factor receptor in high-
grade gliomas and targeting STAT3 sensitizes them to Iressa and
alkylators. Clin Cancer Res 2008, 14:6042-6054.
13. Omuro AMP, Faivre S, Raymond E: Lessons learned in the development of
targeted therapy for malignant gliomas. Mol Cancer Ther 2007,
6:1909-1919.
14. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH,
Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE,
et al: Phase 1 trial of gefitinib plus sirolimus in adults with recurrent
malignant glioma. Clin Cancer Res 2006, 12:860-868.
15. Friedman HS, Bigner DD: Glioblastoma multiforme and the epidermal
growth factor receptor. N Engl J Med 2005, 353:1997-1999.
16. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM,
Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, et al:
Randomized phase II trial of erlotinib versus temozolomide or
carmustine in recurrent glioblastoma: EORTC brain tumor group study
26034. J Clin Oncol 2009, 27:1268-1274.
17. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W,
Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E: A phase I/II trial
of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical
outcomes, pharmacokinetics and molecular correlation. Cancer
Chemother Pharmacol 2009, 65:353-361.
18. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH,
Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH,
Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with
recurrent glioblastoma. J Neurooncol 2010, 96:219-230.
19. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G,
Shih JY, Hung MC: Nuclear Interaction of EGFR and STAT3 in the
Activation of iNOS/NO Pathway. Cancer Cell 2005, 7:575-589.
20. Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW: EGFR and EGFRvIII interact with
PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-
mediated apoptosis independent of EGFR kinase activity. Cancer Lett
2010, 294:101-110.
21. Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, Marie Y,
Poupon MF, Parienti JJ, Raymond E, Peschanski M: Molecular mechanisms
underlying effects of epidermal growth factor receptor inhibition on
invasion, proliferation, and angiogenesis in experimental glioma. Clin
Cancer Res 2009, 15:3697-3704.
22. Mellinghoff IK, Cloughesy TF, Mischel PS: PTEN-Mediated Resistance to
Epidermal Growth Factor Receptor Kinase Inhibitors. Clin Cancer Res 2007,
13:378-381.
23. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L,
Hung MC: Nuclear localization of EGF receptor and its potential new role
as a transcription factor. Nat Cell Biol 2001, 3:802-808.
24. Lo HW, Cao X, Zhu H, Ali-Osman F: Cyclooxygenase-2 is a novel
transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3
signaling axes. Mol Cancer Res 2010, 8:232-245.
25. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC: Novel prognostic
value of nuclear epidermal growth factor receptor in breast cancer.
Cancer Res 2005, 65:338-348.
26. Boerner JL, Demory ML, Silva C, Parsons SJ: Phosphorylation of Y845 on
the epidermal growth factor receptor mediates binding to the
mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004,
24:7059-7071.
27. Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I,
Hüttemann M, Douglas R, Haddad G, Parsons SJ: Epidermal Growth Factor
Receptor Translocation to the Mitochondria. Journal of Biological
Chemistry 2009, 284:36592-36604.
28. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS,
Bigner DD: Characterization of the epidermal growth factor receptor in
human glioma cell lines and xenografts. Cancer Res 1990, 50:8017-8022.
29. Wang Y, Lyu YL, Wang JC: Dual localization of human DNA
topoisomerase IIIalpha to mitochondria and nucleus. Proc Natl Acad Sci
USA 2002, 99:12114-12119.
30. Kutay U, Guttinger S: Leucine-rich nuclear-export signals: born to be
weak. Trends Cell Biol 2005, 15:121-124.
31. la Cour T, Gupta R, Rapacki K, Skriver K, Poulsen FM, Brunak S: NESbase
version 1.0: a database of nuclear export signals. Nucleic Acids Res 2003,
31:393-396.
32. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA,
Dusso A: 1,25-Dihydroxyvitamin D down-regulates cell membrane
growth- and nuclear growth-promoting signals by the epidermal growth
factor receptor. J Biol Chem 2002, 277:38965-38971.
33. Wang SC, Hung MC: Nuclear translocation of the epidermal growth
factor receptor family membrane tyrosine kinase receptors. Clin Cancer
Res 2009, 15:6484-6489.
34. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D,
Burtness BA: Quantitative determination of nuclear and cytoplasmic
epidermal growth factor receptor expression in oropharyngeal
squamous cell cancer by using automated quantitative analysis. Clin
Cancer Res 2005, 11:5856-5862.
35. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY,
Hawke DH, Kobayashi R, Hung MC: Tyrosine phosphorylation controls
PCNA function through protein stability. Nat Cell Biol 2006, 8:1359-1368.
36. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC:
Nuclear expression of epidermal growth factor receptor is a novel
prognostic value in patients with ovarian cancer. Mol Carcinog 2009,
48:610-617.
37. Yue X, Song W, Zhang W, Chen L, Xi Z, Xin Z, Jiang X: Mitochondrially
localized EGFR is subjected to autophagic regulation and implicated in
cell survival. Autophagy 2008, 4:641-649.
Cao et al. Molecular Cancer 2011, 10:26
http://www.molecular-cancer.com/content/10/1/26
Page 12 of 1338. De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C,
Verhofstede C, Eechaute W, Roels H: The subcellular localization of the
neu protein in human normal and neoplastic cells. Int J Cancer 1989,
44:969-974.
39. Vidal GA, Naresh A, Marrero L, Jones FE: Presenilin-dependent gamma-
secretase processing regulates multiple ERBB4/HER4 activities. J Biol
Chem 2005, 280:19777-19783.
40. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S,
Cooke TG, Bartlett JMS, Jones FE: The ERBB4/HER4 Intracellular Domain
4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer Cells.
Cancer Res 2006, 66:6412-6420.
41. Liao HJ, Carpenter G: Role of the Sec61 translocon in EGF receptor
trafficking to the nucleus and gene expression. Mol Biol Cell 2007,
18:1064-1072.
42. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC: Nuclear-
cytoplasmic transport of EGFR involves receptor endocytosis, importin
beta1 and CRM1. J Cell Biochem 2006, 98:1570-1583.
43. Marchenko ND, Zaika A, Moll UM: Death signal-induced localization of
p53 protein to mitochondria. A potential role in apoptotic signaling.
J Biol Chem 2000, 275:16202-16212.
44. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM:
p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003,
11:577-590.
45. Sansome C, Zaika A, Marchenko ND, Moll UM: Hypoxia death stimulus
induces translocation of p53 protein to mitochondria. Detection by
immunofluorescence on whole cells. FEBS Lett 2001, 488:110-115.
46. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W,
Kharbanda S, Kufe D: Human MUC1 carcinoma-associated protein confers
resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163-175.
47. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D: MUC1 oncoprotein is
targeted to mitochondria by heregulin-induced activation of c-Src and
the molecular chaperone HSP90. Oncogene 2006, 25:20-31.
48. Zhao Y, Chaiswing L, Velez JM, Batinic-Haberle I, Colburn NH, Oberley TD, St
Clair DK: p53 translocation to mitochondria precedes its nuclear
translocation and targets mitochondrial oxidative defense protein-
manganese superoxide dismutase. Cancer Res 2005, 65:3745-3750.
49. Lo H-W, Hsu S-C, Xia W, Cao X, Shih J-Y, Wei Y, Abbruzzese JL,
Hortobagyi GN, Hung M-C: Epidermal Growth Factor Receptor
Cooperates with Signal Transducer and Activator of Transcription 3 to
Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-
regulation of TWIST Gene Expression. Cancer Res 2007, 67:9066-9076.
50. Lo HW, Zhu H, Cao X, Aldrich A, Ali-Osman F: A novel splice variant of
GLI1 that promotes glioblastoma cell migration and invasion. Cancer Res
2009, 69:6790-6798.
doi:10.1186/1476-4598-10-26
Cite this article as: Cao et al.: EGFR and EGFRvIII undergo stress- and
EGFR kinase inhibitor-induced mitochondrial translocalization: A
potential mechanism of EGFR-driven antagonism of apoptosis. Molecular
Cancer 2011 10:26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cao et al. Molecular Cancer 2011, 10:26
http://www.molecular-cancer.com/content/10/1/26
Page 13 of 13